Hua Medicine (Shanghai) Ltd
Hua Medicine (Shanghai) Ltd. engages in the development and commercialization of drugs for the treatment of diabetes in China. The company develops HuaTangNing (Dorzagliatin or HMS5552), an oral drug for the treatment of Type 2 Diabetes (T2D); and Dorzagliatin in combination with Metformin, Sitagliptin, and Empagliflozin for treatment of T2D and DKD. It also provides Dorzagliatin in combination w… Read more
Hua Medicine (Shanghai) Ltd (HUMDF) - Net Assets
Latest net assets as of June 2025: $1.06 Billion USD
Based on the latest financial reports, Hua Medicine (Shanghai) Ltd (HUMDF) has net assets worth $1.06 Billion USD as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($1.42 Billion) and total liabilities ($360.82 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $1.06 Billion |
| % of Total Assets | 74.59% |
| Annual Growth Rate | N/A |
| 5-Year Change | -118.49% |
| 10-Year Change | N/A |
| Growth Volatility | 73.62 |
Hua Medicine (Shanghai) Ltd - Net Assets Trend (2016–2024)
This chart illustrates how Hua Medicine (Shanghai) Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Hua Medicine (Shanghai) Ltd (2016–2024)
The table below shows the annual net assets of Hua Medicine (Shanghai) Ltd from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $-135.47 Million | -233.92% |
| 2023-12-31 | $101.15 Million | -63.82% |
| 2022-12-31 | $279.58 Million | -37.92% |
| 2021-12-31 | $450.33 Million | -38.52% |
| 2020-12-31 | $732.50 Million | -30.94% |
| 2019-12-31 | $1.06 Billion | -24.43% |
| 2018-12-31 | $1.40 Billion | +248.91% |
| 2017-12-31 | $-942.53 Million | -41.48% |
| 2016-12-31 | $-666.20 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Hua Medicine (Shanghai) Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 568446300000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $7.21 Million | % |
| Other Comprehensive Income | $286.43 Million | % |
| Other Components | $5.93 Billion | % |
| Total Equity | $-135.47 Million | 100.00% |
Hua Medicine (Shanghai) Ltd Competitors by Market Cap
The table below lists competitors of Hua Medicine (Shanghai) Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
True North Commercial Real Estate Investment Trust
PINK:TUERF
|
$85.24 Million |
|
Sinar Mas Multiartha Tbk
JK:SMMA
|
$85.27 Million |
|
Graphite One Inc
OTCQX:GPHOF
|
$85.28 Million |
|
RattanIndia Enterprises Limited
NSE:RTNINDIA
|
$85.30 Million |
|
Chant Sincere Co Ltd
TW:6205
|
$85.13 Million |
|
Acer E-Enabling Service Business Inc.
TWO:6811
|
$85.13 Million |
|
Maywood Acquisition Corp. Unit
NASDAQ:MAYAU
|
$85.11 Million |
|
Digimarc Corporation
NASDAQ:DMRC
|
$85.09 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Hua Medicine (Shanghai) Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 101,151,000 to -135,466,000, a change of -236,617,000 (-233.9%).
- Net loss of 250,144,000 reduced equity.
- New share issuances of 1,611,000 increased equity.
- Other comprehensive income increased equity by 11,928,999.
- Other factors decreased equity by 12,999.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-250.14 Million | -184.65% |
| Share Issuances | $1.61 Million | +1.19% |
| Other Comprehensive Income | $11.93 Million | +8.81% |
| Other Changes | $-13.00K | -0.01% |
| Total Change | $- | -233.92% |
Book Value vs Market Value Analysis
This analysis compares Hua Medicine (Shanghai) Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | $-0.64 | $0.15 | x |
| 2017-12-31 | $-0.91 | $0.15 | x |
| 2018-12-31 | $3.92 | $0.15 | x |
| 2019-12-31 | $1.13 | $0.15 | x |
| 2020-12-31 | $0.77 | $0.15 | x |
| 2021-12-31 | $0.47 | $0.15 | x |
| 2022-12-31 | $0.29 | $0.15 | x |
| 2023-12-31 | $0.10 | $0.15 | x |
| 2024-12-31 | $-0.14 | $0.15 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Hua Medicine (Shanghai) Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -97.75%
- • Asset Turnover: 0.17x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-78.49%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | -60727.39% | 0.00x | 0.00x | $-294.31 Million |
| 2017 | 0.00% | -2593.57% | 0.04x | 0.00x | $-177.33 Million |
| 2018 | -256.70% | -39464.63% | 0.01x | 1.06x | $-3.74 Billion |
| 2019 | -40.34% | -1922.55% | 0.02x | 1.18x | $-533.96 Million |
| 2020 | -54.12% | -4575.59% | 0.01x | 1.64x | $-469.68 Million |
| 2021 | -73.49% | 0.00% | 0.00x | 2.01x | $-375.98 Million |
| 2022 | -72.88% | -1157.83% | 0.02x | 4.01x | $-231.72 Million |
| 2023 | -208.83% | -275.73% | 0.04x | 17.06x | $-221.35 Million |
| 2024 | 0.00% | -97.75% | 0.17x | 0.00x | $-236.60 Million |
Industry Comparison
This section compares Hua Medicine (Shanghai) Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $548,450,613
- Average return on equity (ROE) among peers: -450.37%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Hua Medicine (Shanghai) Ltd (HUMDF) | $1.06 Billion | 0.00% | 0.34x | $85.17 Million |
| Ascend Wellness Holdings Inc (AAWH) | $142.87 Million | -33.75% | 5.44x | $48.90 Million |
| AB Science S.A (ABSCF) | $10.73 Million | -252.65% | 3.71x | $39.89 Million |
| Alterola Biotech Inc (ABTI) | $4.85K | -2005.32% | 0.49x | $603.58K |
| Aurora Cannabis Inc (ACB) | $2.04 Billion | -34.08% | 0.34x | $199.15 Million |
| Acreage Holdings Inc (ACRDF) | $204.27 Million | -30.85% | 1.41x | $13.48K |
| Acura Pharmaceuticals Inc (ACUR) | $7.90 Million | -63.15% | 1.15x | $13.20K |
| Agra Ventures Ltd. (AGFAF) | $1.51 Million | -44.22% | 0.06x | $298.23K |
| Allergy Therapeutics plc (AGYTF) | $2.07 Million | -2084.75% | 31.32x | $25.30 Million |
| Aida Pharmaceuticals Inc (AIDA) | $6.67 Million | 24.51% | 2.78x | $1.80 |
| Adcock Ingram Holdings Limited (AIHLF) | $3.07 Billion | 20.55% | 0.55x | $85.61 Million |